Cas:383865-57-4 4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-amine manufacturer & supplier

Chemical Name:4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-amine

CAS.NO:383865-57-4

Synonyms:2-amino-4-methoxy-7-morpholin-4-yl-benzothiazol;(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-carbamic acid phenyl ester;7-(morpholin-4-yl)-4-methoxy-benzothiazol-2-ylamine;4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine;2-Benzothiazolamine,4-methoxy-7-(4-morpholinyl);4-Methoxy-7-morpholinobenzo[d]thiazol-2-amine

Molecular Formula:C₁₂H₁₅N₃O₂S

Molecular Weight:265.33100

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:89.58000

Exact Mass:265.08800

LogP:1.71880

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-amino-4-methoxy-7-morpholin-4-yl-benzothiazol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Methoxy-7-morpholinobenzo[d]thiazol-2-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Benzothiazolamine,4-methoxy-7-(4-morpholinyl) Use and application,4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine technical grade,usp/ep/jp grade.

Related News: A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018. 4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-amine manufacturer A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018. 4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-amine supplier A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018. 4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-amine vendor We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries. 4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-amine factory In a statement to Fierce Medtech, Innova said it has completed some corrective actions, while others are still underway, and that the U.S. recall was launched to reclaim tests distributed to employees, clinical studies and to customers for early evaluation. The company said it plans to seek an emergency use authorization and comply with all FDA requirements.